Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Consensus Price Target of $802.18

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus recommendation of “Moderate Buy” from the twenty-six ratings firms that are currently covering the company, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $813.67.

A number of analysts recently weighed in on the stock. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $737.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 29th. Finally, JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a research note on Tuesday.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $738.72 on Wednesday. The company has a market cap of $76.06 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.39 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The business’s 50 day moving average price is $790.36 and its 200-day moving average price is $720.41. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $12.81 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals will post 45.37 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insiders Place Their Bets

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,946 shares of company stock worth $3,302,458 in the last three months. Corporate insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $11,358,000. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $3,342,000. Finally, Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $323,249,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.